Structure-activity relationships of C-17-substituted estratriene-3-O- sulfamates as anticancer agents

Journal of Medicinal Chemistry

Volumn 54, Issue 13, 2011, Pages 4863-4879

  Jourdan, Fabrice ^a   Leese, Mathew P ^a   Dohle, Wolfgang ^a   Ferrandis, Eric ^b   Newman, Simon P ^c   Chander, Surinder ^c   Purohit, Atul ^c   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b Institut de Recherche Henri Beaufour   (France)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA (2 HYDROXYPROPYL) 2 METHOXY 3 O SULFAMOYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 17 (2 ETHOXY 2 OXOETHYLIDENE) 3 O (TERT BUTYLDIMETHYLSILYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 17BETA (2 SULFAMOYLOXYETHYL)ESTRA 3 O SULFAMOYL 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17 (2 HYDROXYETHYLIDENE)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17 (2 METHOXYETHYLIDENE)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA (2 ETHOXY 2 OXOETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA (2 HYDROXYETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA (2 METHOXYETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA (2 TERT BUTYLDIPHENYLSILYLOXYETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA HYDROXYMETHYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA METHOXYMETHYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 HYDROXY 17BETA TERT BUTYLDIPHENYLSILYLOXYMETHYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O BENZYL 17BETA HYDROXYMETHYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O BENZYLOXY 17BETA (2 HYDROXYETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17 (2 ETHOXY 2 OXOETHYLIDENE)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17 (2 METHOXYETHYLIDENE)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17 VINYL ESTRA 1,3,5(10),16 TETRAENE; 2 ETHYL 3 O SULFAMOYL 17BETA (2 ETHOXY 2 OXOETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA (2 METHOXYETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA (2 OXOPROPYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA (HYDROXYETHYL)ESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA ACYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA HYDROXYMETHYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA METHOXYMETHYLESTRA 1,3,5(10)TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA SULFAMOYLOXYMETHYLESTRA 1,3,5(10)TRIENE; 2 METHOXY 3 O HYDROXY 17BETA ACYLESTRA 1,3,5(10)TRIENE; 2 METHOXY 3 O SULFAMOYL 17BETA (2 OXOPROPYL)ESTRA 1,3,5(10)TRIENE; 2 METHOXY 3 O SULFAMOYL 17BETA ACYLESTRA 1,3,5(10)TRIENE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; FEMALE; HUMANS; LAMININ; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRILES; PROTEOGLYCANS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS;

EID: 79960197643     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200483x     Document Type: Article

References (42)

1. Folkman, J.; Bach, M.; Rowe, J. W.; Davidoff, F.; Lambert, P.; Hirsch, C.; Goldberg, A.; Hiatt, H. H.; Glass, J.; Henshaw, E. Tumor angiogenesis-therapeutic implications N. Engl. J. Med. 1971, 285 (21) 1182-1186
2. Ferrara, N.; Hillan, K. J.; Gerber, H. P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discovery 2004, 3 (5) 391-400 (Pubitemid 38618122)
3. Panares, R. L.; Garcia, A. A. Bevacizumab in the management of solid tumors Expert Rev. Anticancer Ther. 2007, 7 (4) 433-445 (Pubitemid 46681799)
4. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discovery 2006, 5 (10) 835-844 (Pubitemid 44480537)
5. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development Nat. Rev. Drug Discovery 2007, 6 (9) 734-745 (Pubitemid 47338181)
6. Kohne, C. H.; Lenz, H. J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist 2009, 14 (5) 478-488
7. Jain, R. K. Taming vessels to treat cancer Sci. Am. 2008, 298 (1) 56-63 (Pubitemid 351182556)
8. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 2005, 8 (4) 299-309 (Pubitemid 41443415)
9. Ebos, J. M. L.; Lee, C. R.; Cruz-Munoz, W.; Bjarnason, G. A.; Christensen, J. G.; Kerbel, R. S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 2009, 15 (3) 232-239
10. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 2009, 15 (3) 220-231
11. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E.; Marcello, J.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D. D.; Friedman, A. H.; Friedman, H. S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J. Clin. Oncol. 2007, 25 (30) 4722-4729 (Pubitemid 350086473)
12. Burger, R. A.; Sill, M. W.; Monk, B. J.; Greer, B. E.; Sorosky, J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J. Clin. Oncol. 2007, 25 (33) 5165-5171 (Pubitemid 350237599)
13. Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity J. Med. Chem. 2006, 49) 7683-7696 (Pubitemid 46033660)
14. Leese, M. P.; Hejaz, H. A. M.; Mahon, M. F.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. A-Ring-substituted estrogen-3- O -sulfamates: potent multitargeted anticancer agents J. Med. Chem. 2005, 48 (16) 5243-5256 (Pubitemid 41113911)
15. Ireson, C. R.; Chander, S. K.; Purohit, A.; Perera, S.; Newman, S. P.; Parish, D.; Leese, M. P.; Smith, A. C.; Potter, B. V. L.; Reed, R. J. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol- bis-sulphamate in vivo in rodents Br. J. Cancer 2004, 90 (4) 932-937 (Pubitemid 38406609)
16. Ho, Y. T.; Purohit, A.; Vicker, N.; Newman, S. P.; Robinson, J. J.; Leese, M. P.; Ganeshapillai, D.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates Biochem. Biophys. Res. Commun. 2003, 305 (4) 909-914 (Pubitemid 36597850)
17. Newman, S. P.; Ireson, C. R.; Tutill, H. J.; Day, J. M.; Parsons, M. F. C.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. The role of 17 beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells Cancer Res. 2006, 66 (1) 324-330 (Pubitemid 43166039)
18. Elger, W.; Schwarz, S.; Hedden, A. M.; Reddersen, G.; Schneider, B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application J. Steroid Biochem. Mol. Biol. 1995, 55 (3-4) 395-403 (Pubitemid 26022205)
19. Reed, M. J.; Purohit, A.; Newman, S. P.; Potter, B. V. L. Steroid sulfatase: molecular biology, regulation and inhibition Endocr. Rev. 2005, 26 (2) 171-202
20. Jourdan, F.; Leese, M. P.; Dohle, W.; Hamel, E.; Ferrandis, E.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17- O, O -bis-sulfamate J. Med. Chem. 2010, 53 (7) 2942-2951
21. Newman, S. P.; Foster, P. A.; Ho, Y. T.; Day, J. M.; Raobaikady, B.; Kasprzyk, P. G.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. The therapeutic potential of a series of orally bioavailable antiangiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers Br. J. Cancer 2007, 97 (12) 1673-1682 (Pubitemid 350249364)
22. Newman, S. P.; Foster, P. A.; Stengel, C.; Day, J. M.; Ho, Y. T.; Judde, J. G.; Lassalle, M.; Prevost, G.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells Clin. Cancer Res. 2008, 14 (2) 597-606 (Pubitemid 351226130)
23. MacCarthy-Morrogh, L.; Townsend, P. A.; Purohit, A.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J.; Packham, G. Differential effects of estrone and estrone-3- O -sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells Cancer Res. 2000, 60 (19) 5441-5450
24. Purohit, A.; Vernon, K. A.; Hummelinck, A. E. W.; Woo, L. W. L.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J. The development of A-ring modified analogues of oestrone-3- O -sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity J. Steroid Biochem. Mol. Biol. 1998, 64 (5-6) 269-275 (Pubitemid 28221630)
25. Purohit, A.; Hejaz, H. A. M.; Walden, L.; MacCarthy-Morrogh, L.; Packham, G.; Potter, B. V. L.; Reed, M. J. The effect of 2-methoxyoestrone-3- O -sulphamate on the growth of breast cancer cells and induced mammary tumours Int. J. Cancer 2000, 85 (4) 584-589 (Pubitemid 30075140)
26. Leese, M. P.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents Bioorg. Med. Chem. Lett. 2004, 14 (12) 3135-3138 (Pubitemid 38624578)
27. Leese, M. P.; Leblond, B.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3- O -sulfamates J. Steroid Biochem. Mol. Biol. 2005, 94 (1-3) 239-251 (Pubitemid 40614537)
28. Leese, M. P.; Jourdan, F. L.; Gaukroger, K.; Mahon, M. F.; Newman, S. P.; Foster, P. A.; Stengel, C.; Regis-Lydi, S.; Ferrandis, E.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents J. Med. Chem. 2008, 51 (5) 1295-1308 (Pubitemid 351480390)
29. Jourdan, F.; Bubert, C.; Leese, M. P.; Smith, A.; Ferrandis, E.; Regis-Lydi, S.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3- O -sulfamates: synthesis, in vitro evaluation and computational modelling Org. Biomol. Chem. 2008, 6 (22) 4108-4119
30. Bubert, C.; Leese, M. P.; Mahon, M. F.; Ferrandis, E.; Regis-Lydi, S.; Kasprzyk, P. G.; Newman, S. P.; Ho, Y. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 3,17-Disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity J. Med. Chem. 2007, 50, 4431-4443 (Pubitemid 47378840)
31. 4/THF Org. Lett. 2004, 6 (26) 4961-4963
32. Okada, M.; Iwashita, S.; Koizumi, N. Efficient general method for sulfamoylation of a hydroxyl group Tetrahedron Lett. 2000, 41 (36) 7047-7051
33. Hartley, R. C.; Li, J. F.; Main, C. A.; McKiernan, G. J. Titanium carbenoid reagents for converting carbonyl groups into alkenes Tetrahedron 2007, 63 (23) 4825-4864 (Pubitemid 46671595)
34. Tsuchiya, T. Chemistry and developments of fluorinated carbohydrates Adv. Carbohydr. Chem. Biochem. 1990, 48, 91-277
35. Chander, S. K.; Foster, P. A.; Leese, M. P.; Newman, S. P.; Potter, B. V. L.; Purohit, A.; Reed, M. J. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol Br. J. Cancer 2007, 96 (9) 1368-1376 (Pubitemid 46685788)
36. Laurence, C.; Brameld, K. A.; Graton, J.; Le Questel, J. Y.; Renault, E. The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 2009, 52 (14) 4073-4086
37. Hollingshead, M.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; Malspeis, L.; Grever, M. R. In vivo cultivation of tumor cells in hollow fibres Life Sci. 1995, 57, 131-141
38. Passaniti, A.; Taylor, R. M.; Pili, R.; Guo, Y.; Long, P. V.; Haney, J. A.; Pauly, R. R.; Grant, D. S.; Martin, G. R. Methods in laboratory investigation-a simple, quantitative method fot assessing angiogenesis and antiangiogenic agents using reconstituted base-membrane, heparin, and fibroblast growth-factor Lab. Invest. 1992, 67 (4) 519-528
39. Prewett, M.; Huber, J.; Li, Y. W.; Santiago, A.; O'Connor, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors Cancer Res. 1999, 59 (20) 5209-5218 (Pubitemid 29503984)
40. Workman, P.; Twentyman, P.; Balkwill, F.; Balmain, A.; Chaplin, D.; Double, J.; Embleton, J.; Newell, D.; Raymond, R.; Stables, J.; Stephens, T.; Wallace, J. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition) Br. J. Cancer 1998, 77 (1) 1-10 (Pubitemid 28029765)
41. Appel, R.; Berger, G. Uber das hydrazidosulfamid (on hydrazidosulfamide) Chem. Ber. 1958, 91, 1339-1341
42. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism J. Steroid Biochem. Mol. Biol. 1996, 57 (1-2) 79-88 (Pubitemid 26150109)